Enhanced Genomics Secures $19M Series A Extension to Advance Therapeutics Pipeline
Biotech secures fresh investment to expand drug discovery in autoimmune and common diseases.
Enhanced Genomics has extended its Series A funding round to a total of $19 million, strengthening its mission to accelerate the discovery of genetically validated drug targets for common diseases. The additional investment, backed by BGF, Parkwalk and Meltwind, will support the company’s internal therapeutics pipeline and fuel new partnerships with pharmaceutical and biotech firms.
The Cambridge-based biotech is pioneering a 3D multi-omics platform that integrates genome-wide 3D interaction data with multi-omics datasets to pinpoint causal biology behind complex diseases. By translating vast amounts of disease-associated genetic data into actionable insights, Enhanced Genomics aims to identify high-confidence therapeutic targets with greater precision, boosting success rates in drug development while reducing time and costs.
The fresh funding will enable the company to expand its programs in autoimmune and other common diseases, including inflammatory bowel disease, areas where unmet medical need remains significant. Enhanced also plans to leverage its platform to scale output through strategic collaborations, offering novel target discovery and asset-based opportunities.
“Enhanced Genomics is uniquely positioned to transform drug discovery,” said Dietrich A. Stephan, Ph.D., Chair of Enhanced Genomics. “Our ability to map causal biology at a genome-wide scale allows us to address complex and common genetic diseases with unprecedented clarity. With the continued support of our investors, we are advancing toward therapies that could redefine standards of care.”
Enhanced Genomics distinguishes itself as the only biotechnology company capable of sourcing genetically validated targets for complex genetic diseases across the genome. Its cell type-specific atlas provides insights into disease mechanisms at unparalleled resolution, allowing researchers to prioritize and identify novel drug targets, as well as stratify patient populations for more effective clinical trials.
Author
BioFocus Newsroom